Nanomedicine News

RSS

Cancer Drug-Packed ‘Grenades’ Armed with Heat Sensitive Triggers Enable Targeted Treatment of Tumours

Researchers have developed cancer drug-packed ‘grenades’ armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

31 Oct 2015

ProNAi Commences Enrollment in 'Brighton' PNT2258 Phase II Trial for Richter's Transformation

ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient into the "Brighton" study, a Phase 2 clinical trial evaluating PNT2258 in patients with Richter's transformation.

31 Oct 2015

New Strategy Provides Cancer Imaging with a Single-Agent Theranostic Nanoplatform

Researchers at Oregon State University today announced an important advance in the field of cancer imaging and phototherapy, using a single-agent system that may ultimately change the efficacy of cancer surgery and treatment around the world.

30 Oct 2015

Celator to Present Data on CombiPlex Technology Platform Applied to MTA Drug Combinations at AACR-NCI-EORTC 2015

Celator Pharmaceuticals, Inc. today announced that data from applying the CombiPlex® technology platform to drug combinations incorporating molecularly targeted agents (MTAs) will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA on November 5-9, 2015.

30 Oct 2015

Ultragenyx and Arcturus Partner to Develop mRNA Therapeutics for Rare Diseases

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus’ UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform.

30 Oct 2015

Biodegradable Nanomedicine Could Selectively Destroy Ovarian Cancer Cells Left Behind After Surgery

Scientists are investigating a biodegradable nanomedicine that can selectively destroy ovarian cancer cells left behind after surgery. These findings are a step forward in the development of targeted therapies for hard-to-treat cancers.

30 Oct 2015

PEN Launches Graphene-Based Product for Diagnostic Imaging Applications

PEN Inc., a global leader in enhanced performance products enabled by nanotechnology to solve everyday problems, today announced the launch of a new graphene-based product for use in the production of nuclear pharmaceuticals used as diagnostic imaging biomarkers.

30 Oct 2015

Nanoparticle-Based Radiotherapeutic Bandage Being Evaluated to Treat Squamous Cell Carcinoma

A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. These results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic.

29 Oct 2015

Pharmasyntez Executes First Order of Oasmia’s Paclical Cancer Product in Russia

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner, Pharmasyntez, has executed the first order of Paclical, Oasmia’s lead cancer product.

29 Oct 2015

New Nanoparticle Targets and Destroys Cells That Cause Cardiac Arrhythmia

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.

29 Oct 2015

Nanomedicine News

Cancer Drug-Packed ‘Grenades’ Armed with Heat Sensitive Triggers Enable Targeted Treatment of Tumours

ProNAi Commences Enrollment in 'Brighton' PNT2258 Phase II Trial for Richter's Transformation

New Strategy Provides Cancer Imaging with a Single-Agent Theranostic Nanoplatform

Celator to Present Data on CombiPlex Technology Platform Applied to MTA Drug Combinations at AACR-NCI-EORTC 2015

Ultragenyx and Arcturus Partner to Develop mRNA Therapeutics for Rare Diseases

Biodegradable Nanomedicine Could Selectively Destroy Ovarian Cancer Cells Left Behind After Surgery

PEN Launches Graphene-Based Product for Diagnostic Imaging Applications

Nanoparticle-Based Radiotherapeutic Bandage Being Evaluated to Treat Squamous Cell Carcinoma

Pharmasyntez Executes First Order of Oasmia’s Paclical Cancer Product in Russia

New Nanoparticle Targets and Destroys Cells That Cause Cardiac Arrhythmia

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

New Nanocage Material Removes Up to 90% of Toxic PFAS from Water

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting